Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended Decembe...(--------------------- ---------------...)

Date:3/5/2009

--------------------- ------------------------------------------------------------------------- Adjusted EBITDA $ 10,331 $ 6,836 $ 37,107 $ 50,566 ------------------------------------------------------------------------- ANGIOTECH PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) As at December 31, December 31, (in thousands of U.S.$) 2008 2007 ------------------------------------------------------------------------- ASSETS Cash and short-term investments $ 39,800 $ 109,225 Accounts receivable 25,524 22,678 Inventories 38,594 33,647 Deferred income taxes 3,820 5,964 Other current assets 5,234 7,070 ------------------------------------------------------------------------- Total current assets 112,972 178,584 ------------------------------------------------------------------------- Long-term investments 1,561 6,557 Assets held for sale 8,422 - Property and equipment, net 49,108 59,187 Intangible assets, net 195,477 225,889 Goodwill - 659,511 Deferred financing costs 11,363 13,600 Other assets 6,294 6,780 ------------------------------------------------------------------------- Total assets $ 385,197 $ 1,150,
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
2. Angiotech Pharmaceuticals announces time change of conference call and webcast
3. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
4. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
5. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
6. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
7. Angiotech wins before the UK House of Lords
8. Angiotech to Establish Separate Operating and Royalty Businesses
9. Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
10. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study